Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/77652
Campo DC Valoridioma
dc.contributor.authorMarco-Benedí, Victoriaen_US
dc.contributor.authorLaclaustra, Martínen_US
dc.contributor.authorBea, Ana M.en_US
dc.contributor.authorSuárez-Tembra, Manuelen_US
dc.contributor.authorPlana, Núriaen_US
dc.contributor.authorPinto, Xavieren_US
dc.contributor.authorBrea, Angelen_US
dc.contributor.authorSánchez Hernández, Rosa Maríaen_US
dc.contributor.authorCiveira, Fernandoen_US
dc.date.accessioned2021-02-10T14:36:12Z-
dc.date.available2021-02-10T14:36:12Z-
dc.date.issued2021en_US
dc.identifier.issn0021-9150en_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/77652-
dc.description.abstractBackground and aims: Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by a high risk of cardiovascular disease when not in lipid-lowering treatment. However, there is a large variability in the clinical presentation in heterozygous subjects (HeFH). Maternal hypercholesterolemia has been proposed as a cardiometabolic risk factor later in life. Whether this phenotype variability depends on the mother or father origin of hypercholesterolemia is unknown. The objective of this study was to analyze potential differences in anthropometry, superficial lipid deposits, comorbidities, and lipid concentrations depending on the parental origin of hypercholesterolemia within a large group of HeFH. Methods: This is a cross-sectional observational, multicenter, nation-wide study in Spain. We recruited adults with HeFH to study clinical differences according to the parental origin. Data on HeFH patients were obtained from the Dyslipidemia Registry of the Spanish Atherosclerosis Society. Results: HeFH patients were grouped in 1231 HeFH-mother-offspring aged 45.7 (16.3) years and 1174 HeFH-father-offspring aged 44.8 (16.7) years. We did not find any difference in lipid parameters (total cholesterol, triglycerides, LDLc, HDLc, and Lp(a)), nor in the comorbidities studied (cardiovascular disease prevalence, age of onset of cardiovascular disease, obesity, diabetes, and hypertension) between groups. Lipid-lowering treatment did not differ between groups. The prevalence of comorbidities did not show differences when they were studied by age groups. Conclusions: Our research with a large group of subjects with HeFH shows that a potential maternal effect is not relevant in FH. However, due to the size of our sample, potential differences between genders cannot be completely ruled out. This implies that severe maternal hypercholesterolemia during pregnancy is not associated with additional risk in the FH affected offspring.en_US
dc.languageengen_US
dc.relation.ispartofAtherosclerosisen_US
dc.sourceAtherosclerosis [ISSN 0021-9150],v. 320, p. 47-52, (Marzo 2021)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320702 Artereoesclerosisen_US
dc.subject320501 Cardiologíaen_US
dc.subject.otherHefh Phenotypeen_US
dc.subject.otherHeterozygous Familial Hypercholesterolemiaen_US
dc.subject.otherLow-Density Lipoprotein Receptoren_US
dc.subject.otherMother-Offspringen_US
dc.titleMaternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemiaen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.atherosclerosis.2021.01.015en_US
dc.identifier.scopus85100017213-
dc.contributor.authorscopusid57189493797-
dc.contributor.authorscopusid10046356900-
dc.contributor.authorscopusid35331896600-
dc.contributor.authorscopusid6507919181-
dc.contributor.authorscopusid57217124125-
dc.contributor.authorscopusid57214783328-
dc.contributor.authorscopusid56896092400-
dc.contributor.authorscopusid35197086100-
dc.contributor.authorscopusid35517335700-
dc.identifier.eissn1879-1484-
dc.description.lastpage52en_US
dc.description.firstpage47en_US
dc.relation.volume320en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages6en_US
dc.utils.revisionen_US
dc.date.coverdateMarzo 2021en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,399
dc.description.jcr6,847
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
dc.description.miaricds11,0
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0003-4991-7445-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameSanchez Hernández, Rosa María-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

7
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

7
actualizado el 17-nov-2024

Visitas

81
actualizado el 13-abr-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.